Maine Biotechnology Services Inc.

Specializes in the contract development of hybridoma cell lines, monoclonal and polyclonal antibody production, antibody purification, fragmentation and conjugation, and immunoassay development for diagnostic and research use. The company performs large-scale antibody production using ascites or in vitro methods, and offers a comprehensive range of high-quality premade monoclonal and polyclonal antibodies for commercial end-product manufacturing. The company is the first U.S. antibody company to be 1774EC registered for both polyclonal and monoclonal antibodies for European sale.